Switch theme
Sign up to access all valuation multiples
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.
2008
283
LTM Revenue $149M
LTM EBITDA -$228M
$3.7B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Rhythm Pharmaceuticals has a last 12-month revenue (LTM) of $149M and a last 12-month EBITDA of -$228M.
In the most recent fiscal year, Rhythm Pharmaceuticals achieved revenue of $130M and an EBITDA of -$238M.
Rhythm Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Rhythm Pharmaceuticals valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $149M | XXX | $130M | XXX | XXX | XXX |
| Gross Profit | $134M | XXX | $117M | XXX | XXX | XXX |
| Gross Margin | 90% | XXX | 90% | XXX | XXX | XXX |
| EBITDA | -$228M | XXX | -$238M | XXX | XXX | XXX |
| EBITDA Margin | -153% | XXX | -183% | XXX | XXX | XXX |
| EBIT | -$225M | XXX | -$266M | XXX | XXX | XXX |
| EBIT Margin | -151% | XXX | -204% | XXX | XXX | XXX |
| Net Profit | -$225M | XXX | -$261M | XXX | XXX | XXX |
| Net Margin | -151% | XXX | -200% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Rhythm Pharmaceuticals's stock price is $61.
Rhythm Pharmaceuticals has current market cap of $3.9B, and EV of $3.7B.
See Rhythm Pharmaceuticals trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $3.7B | $3.9B | XXX | XXX | XXX | XXX | $-3.66 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Rhythm Pharmaceuticals has market cap of $3.9B and EV of $3.7B.
Rhythm Pharmaceuticals's trades at 28.7x EV/Revenue multiple, and -15.7x EV/EBITDA.
Equity research analysts estimate Rhythm Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Rhythm Pharmaceuticals has a P/E ratio of -17.3x.
See valuation multiples for Rhythm Pharmaceuticals and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $3.9B | XXX | $3.9B | XXX | XXX | XXX |
| EV (current) | $3.7B | XXX | $3.7B | XXX | XXX | XXX |
| EV/Revenue | 25.1x | XXX | 28.7x | XXX | XXX | XXX |
| EV/EBITDA | -16.4x | XXX | -15.7x | XXX | XXX | XXX |
| EV/EBIT | -16.6x | XXX | -14.1x | XXX | XXX | XXX |
| EV/Gross Profit | 28.0x | XXX | n/a | XXX | XXX | XXX |
| P/E | -17.3x | XXX | -15.0x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -32.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialRhythm Pharmaceuticals's last 12 month revenue growth is 54%
Rhythm Pharmaceuticals's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $1.4M for the same period.
Rhythm Pharmaceuticals's rule of 40 is -163% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Rhythm Pharmaceuticals's rule of X is -17% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Rhythm Pharmaceuticals and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 54% | XXX | 54% | XXX | XXX | XXX |
| EBITDA Margin | -153% | XXX | -183% | XXX | XXX | XXX |
| EBITDA Growth | -33% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -163% | XXX | -129% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -17% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.5M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.4M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 183% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 294% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Rhythm Pharmaceuticals acquired XXX companies to date.
Last acquisition by Rhythm Pharmaceuticals was XXXXXXXX, XXXXX XXXXX XXXXXX . Rhythm Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Rhythm Pharmaceuticals founded? | Rhythm Pharmaceuticals was founded in 2008. |
| Where is Rhythm Pharmaceuticals headquartered? | Rhythm Pharmaceuticals is headquartered in United States of America. |
| How many employees does Rhythm Pharmaceuticals have? | As of today, Rhythm Pharmaceuticals has 283 employees. |
| Who is the CEO of Rhythm Pharmaceuticals? | Rhythm Pharmaceuticals's CEO is Dr. David P. Meeker,M.D.. |
| Is Rhythm Pharmaceuticals publicy listed? | Yes, Rhythm Pharmaceuticals is a public company listed on NAS. |
| What is the stock symbol of Rhythm Pharmaceuticals? | Rhythm Pharmaceuticals trades under RYTM ticker. |
| When did Rhythm Pharmaceuticals go public? | Rhythm Pharmaceuticals went public in 2017. |
| Who are competitors of Rhythm Pharmaceuticals? | Similar companies to Rhythm Pharmaceuticals include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Rhythm Pharmaceuticals? | Rhythm Pharmaceuticals's current market cap is $3.9B |
| What is the current revenue of Rhythm Pharmaceuticals? | Rhythm Pharmaceuticals's last 12 months revenue is $149M. |
| What is the current revenue growth of Rhythm Pharmaceuticals? | Rhythm Pharmaceuticals revenue growth (NTM/LTM) is 54%. |
| What is the current EV/Revenue multiple of Rhythm Pharmaceuticals? | Current revenue multiple of Rhythm Pharmaceuticals is 25.1x. |
| Is Rhythm Pharmaceuticals profitable? | Yes, Rhythm Pharmaceuticals is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Rhythm Pharmaceuticals? | Rhythm Pharmaceuticals's last 12 months EBITDA is -$228M. |
| What is Rhythm Pharmaceuticals's EBITDA margin? | Rhythm Pharmaceuticals's last 12 months EBITDA margin is -153%. |
| What is the current EV/EBITDA multiple of Rhythm Pharmaceuticals? | Current EBITDA multiple of Rhythm Pharmaceuticals is -16.4x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
